z-logo
open-access-imgOpen Access
The rules for predicting remission in patients with Cushing disease after successful endoscopic transnasal adenomectomy
Author(s) -
Elena Y. Nadezhdina,
O. Yu. Rebrova,
Andrey Grigoriev
Publication year - 2020
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl10149
Subject(s) - morning , medicine , cushing's disease , retrospective cohort study , surgery , disease
BACKGROUND: The recurrence rate after successful transnasal adenomectomy in Cushings disease (CD) can reach 47%. We have previously shown that patients with ACTH levels less than 7 pg/ml recurred over 3 years 4.5 times less often than patients with higher levels of ACTH, patients with cortisol levels below 123 nmol/l in 3.4 times less than at higher values of this hormone, however, these indicators are dissociated in 41% of cases, so it is not possible use them for prediction separately. AIM: To develop a method for managing patients after successful transnasal adenomectomy depending on prognosis. METHODS: A monocenter retrospective comparative study included 349 patients (52 men, 297 women) with a confirmed diagnosis of CD, who underwent effective endoscopic transsphenoidal adenomectomy in 20072014. Various combinations of postoperative morning levels of ACTH and cortisol were analyzed. RESULTS: Based on the developed forecasting methods and their best characteristics, the following rules were formulated. If postoperative morning ACTH is less than 7 pg/ml and/or postoperative morning cortisol is less than 123 nmol/l, then the patient will remain in remission for 1 year with probability of 99% (95% CI 97%100%) and for 3 years with probability of 86% (95% CI 80%91%). CONCLUSION: The rules for predicting remission for 1 and 3 years for patients after neurosurgical treatment for CD are proposed. These rules are based on combinations of ACTH and cortisol levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here